Posted by Michael Wonder on 17 Nov 2020
PLx Pharma submits supplemental new drug applications for Vazalore 325 mg and 81 mg to U.S. FDA
16 November 2020 - FDA sets estimated completion review date for the end of February 2021.
PLx Pharma announced today that two chemistry and manufacturing control supplemental new drug applications, one for Vazalore 325 mg and one for Vazalore 81 mg dose, were submitted to the U.S. FDA in October for regulatory approval.
